Company intelligence / Profile preview
SymbioCellTech
Salt Lake City, Utah, United Statessymbiocelltech.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Preclinical studies have shown promising results for Neo-Islets in treating Type 1 diabetes. A clinical trial in diabetic pet dogs yielded up to 50% reduction in insulin needs and ~100mg/dL reduction in blood glucose levels, sustained for over 15 months.
- Therapeutic areas
- EndocrinologyCardiovascularNephrology
- Modalities
- Cell therapyStem cell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Virbac (veterinary pharmaceutical group)
Beyond the preview
Go deeper on SymbioCellTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SymbioCellTech.